Medicus Pharma Advances Skinject Toward FDA Path for Rare Skin Cancer Disorder

Medicus Pharma (NASDAQ: MDCX) announced the submission of a Skinject clinical protocol to the FDA under its existing investigational new drug (IND) application, marking another step forward in the company’s development strategy for its microneedle-based skin cancer therapy. The protocol is focused on Gorlin syndrome, a rare inherited condition linked to recurring basal cell carcinomas and repeated surgical procedures.

The proposed Phase 2b open-label study is designed to generate efficacy and safety data intended to support a future new drug application (NDA) for Skinject in patients with Gorlin syndrome. Medicus says the filing expands the clinical development pathway for Skinject as it advances treatment options for difficult-to-manage skin cancer conditions.

#MedicusPharma
#MDCX
#Biotech
#SkinCancer
#BasalCellCarcinoma
#ClinicalTrials
#FDA
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Dermatology
#RareDisease
#Pharmaceuticals
#JaneKing
#NewsOut